NCT02175355View on ClinicalTrials.gov

Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,039

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

August 31, 2000

Conditions
Hypertension
Interventions
DRUG

Low dose of Micardis®

DRUG

Medium dose of Micardis®

DRUG

High dose of Micardis®

DRUG

Hydrochlorothiazide

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02175355 - Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) | Biotech Hunter | Biotech Hunter